Status:
COMPLETED
A Study of Letrozole in the Treatment of Endometrial Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Canadian Cancer Trials Group
Conditions:
Recurrent and Metastatic Endometrial Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Postmenopausal women with recurrent or metastatic adeno- or adenosquamous carcinoma of the endometrium
- No adjuvant therapy
- Up to one prior hormonal (progestin) therapy for advanced/metastatic disease allowed
- No chemotherapy for recurrence (adjuvant permitted)
- Unidimensionally measurable disease
- Good Health status 0-2 (Eastern Cooperatitve Oncology Group)
- No prior tamoxifen or aromatase inhibitor therapy
- No other concurrent anti-cancer treatment
- No metastases in the central nervous system
- Exclusion criteria:
- Additional protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00333086
Start Date
January 1 2000
Last Update
April 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Heidelberg, Germany